GlassScriptPhysician profile
Khidir A Osman
NPI 1386742864
$18,823.49
in general payments reported to CMS, 2019-2025
17 companies · $9,478 in 2025
The $9,478 reported for 2025 was more than what 94% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $5,301 · 2020: $465 · 2021: $825 · 2022: $1,460 · 2023: $911 · 2024: $383 · 2025: $9,478.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $8,319 · Food and Beverage: $2,453.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $8,318.64 |
| Food and Beverage | $2,453.07 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $11,003.90 | 2021-2025 | Micra, Cobalt Dr Mri Surescan, Symplicity G3 |
| Medtronic Vascular, INC. | $5,600.66 | 2019-2020 | |
| Abiomed | $883.53 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $435.68 | 2022-2025 | Verquvo |
| Novartis Pharmaceuticals Corporation | $242.79 | 2019-2025 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $171.05 | 2020-2025 | Lifevest |
| Boehringer Ingelheim Pharmaceuticals, INC. | $99.64 | 2023-2025 | Jardiance |
| Amgen INC. | $98.71 | 2019-2022 | |
| Astellas Pharma US INC | $94.52 | 2019 | |
| Actelion Pharmaceuticals US, INC. | $58.31 | 2022-2025 | Opsumit |
| E.R. Squibb & Sons, L.L.C. | $29.63 | 2022 | |
| Abbott Laboratories | $27.93 | 2022 | |
| Boston Scientific Corporation | $19.37 | 2023 | Watchman Access System |
| Chiesi USA, INC. | $17.53 | 2023 | Cleviprex, Kengreal |
| Cardiovascular Systems INC. | $14.87 | 2021 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Terumo Medical Corporation | $13.32 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $12.05 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Khidir Osman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.